

July 7, 2016

It is with great sadness and heavy heart, I write to inform you that Lawrence Bock died at his home last evening. Larry waged a monumental battle with pancreatic cancer, an effort only a man with his commitment to science and medicine could undertake. His dedication to family, friends and his personal projects continued with his active support to the end. Larry will be remembered as a brilliant entrepreneur, passionate philanthropist and dedicated family man. His passing is a profound loss but his legacy will live on for many years through the continuation of the Festival and many others of his start-up projects.

Larry Bock was the Founder and Principal of Science Spark, a 501(c)3 non-profit corporation, and was the founder of the USA Science & Engineering Festival which has attracted millions of participants after only 4 festivals. In 2008, Larry launched the San Diego Science Festival to educate and inspire our next generation to pursue STEM careers. Today, that original vision has grown into the nation's largest science festival in Washington, D.C., and an organization with a global impact on STEM education—a testimony to Larry's enduring impact on the future of discovery and innovation!

Larry was actively involved in Science Spark and the Festival until the very end, and his vision, dedication, and mostly his humor and support of this work, will be sincerely missed. We extend our deepest condolences to his beloved family – his wife, Diane, and his daughters, Tasha and Quincy (and Quincy's husband, John) and his service dog, Tripp. Larry's blindness was not normally evident to the people he worked with.

The pride that Larry took in his many professional achievements was surpassed only by his pride in his two daughters, the ultimate expression of his joie de vivre. The "Festival Family" the Bock's have created owes a lifetime of gratitude for the millions of young students their festival has inspired.

In addition to his work with Science Spark, Larry was a serial entrepreneur who founded, co-founded or financed the early stage growth of 40 companies from inception to an aggregate market capitalization of \$70 Billion. Mr. Bock was a General Partner of CW Ventures, a 100M life sciences venture capital fund, and a Special Limited Partner to Lux Capital, a 100M nanotechnology-focused venture capital fund. Prior to that, he spent nine years as a partner at Avalon Ventures with his friend, Kevin Kinsella. He was a Member of the Board of Directors of FEI Corporation (NASDAQ: FEIC), the leading supplier of tools for nanotechnology research.



Mr. Bock started his career as a Researcher in the early days at <u>Genentech, Inc.</u> in the field of infectious diseases, where he was on the team that received the <u>AAAS Newcomb</u> <u>Cleveland Prize</u> for demonstrating the world's first recombinant DNA vaccine. His most recent venture, <u>Aira</u>, a visual services company for the blind in which he co-founded. He was a Venture Capital Associate with Fairfield Ventures (now Oxford Bioventures)

He has received several awards and honors. Mr. Bock was selected as by the US Commission for UNESCO as the nominee representing the United States of America in the international competition for the 2011 Kalinga Prize for the Popularization of Science. He was a recipient of the Hoyt S. Vandenberg Prize from the Air Force Association for the best STEM Education Program and also of the 2014 Viktor Hamburger Outstanding Educator Prize of the Society of Developmental Biology. He was selected by Venture Capital Journal as one of the "Ten Most Influential Venture Capitalists," by Red Herring as one of the "Top Ten Innovators," by Forbes-Wolfe NanoReport as the "Number One Powerbroker in Nanotechnology," by Ernst & Young as a Finalist for "Entrepreneur of the Year," and by Small Times as "Innovator of the Year" and "Top 3 Business Leaders of the Year." He received the Einstein Award by the Jerusalem Foundation for lifetime contributions in the field of life sciences. He was one of a dozen individuals invited to the signing of the 3.7B 21st Century Nanotechnology Act by President George Bush in the Oval Office.

Mr. Bock was the Founder and Initial CEO of Neurocrine Biosciences (NASDAQ: NBIX - neuroimmunology), Nanosys Inc., Pharmacopeia (NASDAQ: PCOP - combinatorial chemistry (which spun off Accelrys (NASDAQ: ACCL – computer-aided-drug and material discovery)), GenPharm International (Private – transgenic animals, acquired by Medarex for 100M and also spun off Pharming Group N.V.), Caliper Technologies (NASDAQ: CALP – lab-on-a-chip and subsequently acquired by Perkin Elmer for \$650 Million), Illumina Technologies (NASDAQ: ILMN - human genotyping), IDUN Pharmaceuticals (Private – apoptosis, acquired by Pfizer (NYSE: PFE) for 250M)) Metra Biosystems (NASDAQ: MTRA – musculoskeletal disease diagnosis, merged with Quidel (NASDAQ: QDEL)), and FASTTRACK Systems (Private – accelerated clinical drug development). Mr. Bock was a co-founder of Argonaut Technologies (NASDAQ: AGNT – automated chemistry merged with Biotope (NASDAQ: BIOT)), ARIAD Pharmaceuticals (NASDAQ: ARIA – intra cellular signal transduction), Athena Neurosciences (NASDAQ: ATHN – molecular neurobiology, acquired by Elan Pharmaceuticals (NYSE: ELN) for 700M)), Vertex Pharmaceuticals (NASDAO: VRTX - rational drug design), and Onyx Pharmaceuticals (NASDAQ: ONXX - molecular oncology). He also helped found and was previously on the Scientific Advisory Board of Conforma Therapeutics (Private – cellular chaperones – acquired by Pfizer for 250M).

Mr Bock was a seed stage investor in <u>Acceleron Pharma</u> (Private – metabolic and musculoskeletal diseases), <u>Aurora Biosciences</u> (NASDAQ: ABSC – high throughput drug discovery, acquired by <u>Vertex Pharmaceuticals</u> for 650M), <u>Cambrios</u> (Priviae – biology directed electronic assembly), <u>River Medical</u> (Private – drug delivery, purchased IVAC from <u>Eli Lily</u> in an LBO and did a 700M merger with IMED to form <u>Alaris</u> <u>Medical</u> (NASDAQ: AMI – medical devices)), <u>Genocea Biosciences</u> (Private – vaccine



development) Plexikon Pharmaceuticals (Private – scaffold based drug design which was acquired by Daiihi Sankyo for \$800 M) Poland Partners (Private - a 62.5M venture capital fund investing in Central Europe), Sequana Therapeutics (NASDAQ: SQNA - genomics, merged with Arris Pharmaceuticals to form AXYS Pharmaceuticals (NASDAQ: AXPH) and subsequently acquired by Celera Genomics (NASDAQ: CRA)), Sirtris Pharmaceuticals (Private – gene regulation), Software Transformation (Private – object based software programming, acquired by Novell (NASDAQ: NOVL) for 25M), Surface Logix (Private – nano- imprint lithography), and Talarian (NASDAQ: TALR – real time, high content information processing over distributed networks merged with TIBCO (NASDAQ: TIBX)). He is also was previously on the Scientific Advisory Board of Protia L.L.C.

Larry was also an early stage venture investor in <u>Biosym Technologies</u> (Private – computer-aided-drug discovery – acquired by <u>Corning</u> (NYSE: GLW) for \$250M. <u>Gen-Probe</u> (NASDAQ: GNPR – DNA diagnostics, acquired by <u>Chugai Pharmaceuticals</u> for 180M), <u>Gensia Pharmaceuticals</u> (NASDAQ: GNSA – cardiovascular drugs, merged with Sicor to become <u>Gensia-Sicor</u> and subsequently acquired by <u>TEVA</u> <u>Pharmaceuticals</u> (NASDAQ: TEVA)), <u>IDEC Pharmaceuticals</u> (NASDAQ: IDEC – monoclonal antibody therapy, merged with Biogen to become <u>Biogen Idec</u> (NASDAQ: BIIB)), <u>Oclassen Pharmaceuticals</u> (Private – dermatology, acquired by <u>Watson</u> <u>Pharmaceuticals</u> (NYSE: WPI) for 180M), and <u>Viagene</u> (Private – gene therapy, acquired by <u>Chiron Corporation</u> for 100M).

Mr. Bock was involved in a number of government agencies. He was a Member of the Advisory Board and the Technology Advisory Board of the NanoBusiness Alliance. He previously served as a Member of the Nanotechnology Technical Advisory Group (NTAG) reporting to the President's Council of Advisors on Science and Technology (PCAST), a Member of the Blue Ribbon Task Force on Nanotechnology formed by Congressman Mike Honda and California State Controller Steven Westly. He was on the Advisory Board of the Faculty of Chemistry at the University of California, Berkeley.

Larry and his wife, Diane, established the Larry and Diane Bock Chair in Nanotechnology at the University of California, Berkeley held by <u>Dr. Paul Alivisatos</u>. They also founded <u>Community Cousins</u>, a non-profit foundation focused on breaking down racial barriers, which was selected by former Vice President Al Gore as one of ten outstanding grass root efforts nationally.

Larry received his B.A. in Biochemistry (summa cum laude) from <u>Bowdoin College</u> and his M.B.A. from the <u>Anderson School at UCLA</u>.

Larry's accomplishments in life were a testament to his brilliance, passion, drive and love. He has been taken from us much too early. His future was bright with new endeavors and passions.

The Festival Family, supporters and sponsors have lost their trailblazer. The Festival legacy will continue in honor of the work Larry inspired.



In lieu of flowers or gifts, contributions may be made to <u>Science Spark</u> for producing the continuation of the USA Science and Engineering Festival, his crowning achievement. The Festival combines his love of science, entrepreneurship, jovial spirit, sense of adventure and his fondest hopes and dreams as a Dad.

Best Regards,

Marc Schulman Executive Director USA Science and Engineering Festival

